Compare Agilysys Inc (AGYS) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilysys Inc vs Smith & Nephew plc — how do they compare? Agilysys Inc trades at $106.33 (market cap $3.00B), while Smith & Nephew plc trades at $29.77 (market cap $12.54B). The key difference: Smith & Nephew plc is far larger — about 4.2× Agilysys Inc's market cap, and Smith & Nephew plc pays a 2.65% dividend while Agilysys Inc pays none. Which is the better fit depends on your goals.
| AGYS | SNN | |
|---|---|---|
Market Cap | $3.00B | $12.54B |
Sector | Technology | Health |
52-Week High | $141.12 | $38.70 |
52-Week Low | $62.19 | $28.73 |
Enterprise Value | $2.90B | $15.57B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilysys (AGYS) trades at $104.92, down 1.93% on the day, with a bullish technical signal and strong analyst support. Recent Q1 2027 earnings beat expectations, driven by subscription growth and record revenue, prompting raised full-year guidance. The stock shows robust fundamentals with a 63.06% gross margin and 12.99% net income margin, though valuations are elevated with a P/E of 70.01. Institutional sentiment is positive, with all 9 analysts rating it a Buy and a consensus price target of $118.33.
Outlook remains favorable due to earnings momentum and AI-driven hospitality solutions, but risks include high valuation sensitivity and competitive pressures. Upside potential is supported by analyst targets, yet investors should monitor execution on growth forecasts and market volatility.
Smith & Nephew (SNN) trades at $29.76, down 1.06% with bearish technical signals. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B and net income margin expanding to 10.08% in 2025. Recent Q2 2026 earnings beat expectations but the company lowered full-year revenue guidance from 6% to 4% growth due to U.S. Orthopaedics weakness.
While valuation multiples appear reasonable (P/E 20.41, EV/EBITDA 9.9), the stock faces headwinds from mixed earnings performance and cautious analyst sentiment. The primary investment case hinges on execution in robotics and wound care segments offsetting orthopedic challenges, with downside risk from continued U.S. market softness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilysys Inc
Agilysys provides enterprise software and SaaS solutions for the hospitality industry. Its products specialize in point-of-sale, property management, and inventory systems for hotels, resorts, and cruise lines.
Read more on AGYS →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
